IMV Reports Positive Data for Covid-19 Vaccine Candidate
IMV Reports Positive Data for Covid-19 Vaccine Candidate
DJ IMV Reports Positive Data for Covid-19 Vaccine Candidate
By Chris Wack
IMV Inc. said Monday it is encouraged by data generated so far for its vaccine candidate, DPX-Covid-19, for the prevention of Covid-19 infection.
The biopharmaceutical company said it has successfully completed preclinical safety and good laboratory practice, or GLP, toxicology studies, as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
IMV said it is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in the first quarter of 2021 on its revised clinical plan.
None of the recent mutations reported in U.K. or in Denmark are in the areas of the four selected peptides in DPX-Covid-19. By targeting areas less prone to mutations, DPX-Covid-19 has potential to offer protection against a broader range of circulating variants, the company said.
IMV said the completed safety studies confirmed a favorable safety profile and showed potential for long-term protection with antibody titers maintained throughout the duration of studies.
The company also said it has entered into a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-Covid-19 in India and Europe with the anticipated capacity to produce several hundred million doses.
IMV shares were up 30% to $3.94 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 28, 2020 07:27 ET (12:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
DJ IMV Reports Positive Data for Covid-19 Vaccine Candidate
DJ IMV報告新冠肺炎候選疫苗的陽性數據
By Chris Wack
克里斯·瓦克(Chris Wack)著
IMV Inc. said Monday it is encouraged by data generated so far for its vaccine candidate, DPX-Covid-19, for the prevention of Covid-19 infection.
IMV公司週一表示，到目前為止為其候選疫苗DPX-新冠肺炎提供的預防新冠肺炎感染的數據令他們感到鼓舞。
The biopharmaceutical company said it has successfully completed preclinical safety and good laboratory practice, or GLP, toxicology studies, as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
這家生物製藥公司表示，它已經成功完成了臨牀前安全性和良好的實驗室實踐，即GLP，毒理學研究，以及免疫原性和挑戰性研究，證實了良好的安全性概況和長期抗體滴度和對SARS-CoV-2的保護潛力。
IMV said it is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in the first quarter of 2021 on its revised clinical plan.
IMV表示，它正計劃進行補充性臨牀前研究，包括測試新的變種，並將在2021年第一季度提供修訂後的臨牀計劃的最新情況。
None of the recent mutations reported in U.K. or in Denmark are in the areas of the four selected peptides in DPX-Covid-19. By targeting areas less prone to mutations, DPX-Covid-19 has potential to offer protection against a broader range of circulating variants, the company said.
最近在英國或丹麥報道的突變都不在DPX-新冠肺炎中選定的四個肽的區域。該公司表示，通過瞄準不太容易發生突變的地區，DPX-新冠肺炎有可能提供保護，抵禦更廣泛的流通變體。
IMV said the completed safety studies confirmed a favorable safety profile and showed potential for long-term protection with antibody titers maintained throughout the duration of studies.
IMV説，完成的安全性研究證實了有利的安全性概況，並顯示出在整個研究期間保持抗體效價的長期保護潛力。
The company also said it has entered into a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-Covid-19 in India and Europe with the anticipated capacity to produce several hundred million doses.
該公司還表示，它已經與一家全球製造合作伙伴建立了合作關係，並啟動了DPX-新冠肺炎在印度和歐洲的轉移和擴大活動，預計將有數億劑的生產能力。
IMV shares were up 30% to $3.94 in premarket trading.
IMV股價在盤前交易中上漲30%，至3.94美元。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
December 28, 2020 07:27 ET (12:27 GMT)
2020年12月28日東部時間07：27(格林尼治標準時間12：27)
Copyright (c) 2020 Dow Jones & Company, Inc.
版權所有(C)2020道瓊斯公司。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧